CENTESSA PHARMACEUTICALS PLC

Figures converted to GBP from USD at 0.744 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. CENTESSA PHARMACEUTICALS PLC 2021-05-14 → present
2. CENTESSA PHARMACEUTICALS LIMITED 2021-02-17 → 2021-05-14
3. UNITED MEDICINES BIOPHARMA LIMITED 2020-10-26 → 2021-02-17

Accounting basis

US GAAP

Reporting scope

Consolidated group

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The directors have prepared the financial statements on the going concern basis as they do not intend to liquidate the Group or the Parent Company or to cease their operations, and as they have concluded that the Group's and the Parent Company's financial position means that this is realistic; they have also concluded that there are no material uncertainties that could have cast significant doubt over their ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").”

Group structure

1. CENTESSA PHARMACEUTICALS PLC · parent
   1. Centessa Pharmaceuticals Holdings Inc. 100% · USA · Corporate Services
   2. Centessa Pharmaceuticals (UK) Limited 100% · UK · Corporate Services & Research and Development
   3. Z Factor Limited 100% · UK · Research & Development
   4. ApcinteX Limited 100% · UK · Research & Development
   5. Centessa Pharmaceuticals LLC 100% · USA · Corporate Services
   6. Centessa Biosciences Inc formerly known as Palladio Biosciences Inc 100% · USA · Research & Development

Significant events

• “On February 14, 2025, Centessa Pharmaceuticals (UK) Limited ("Centessa"), a wholly-owned subsidiary of Centessa Pharmaceuticals plc (the "Company") entered into a License Agreement (the "License Agreement") with Genmab A/S ("Genmab") pursuant to which Centessa granted Genmab an exclusive worldwide license...”
• “On September 28, 2022 ("Original Complaint"), the Company and certain of its current and former directors were named as defendants in a proposed class action lawsuit filed in the United States District Court for the Central District of California.”
• “On August 2, 2024, Judge Gregory Wood of the United States District Court for the Southern District of New York granted in full a motion to dismiss with leave for the plaintiff to amend within twenty-one days certain statements and no leave to amend other statements and no ability to expand the scope of the claims pleaded in the Amended Complaint.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

15

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.